Congratulations to February winner: Masoumeh Azizi!
Get involved in any activity of the Beta Cells in Diabetes website, and we'll enter you in a monthly drawing for this pair of educational resources from The Endocrine Society:
- Endocrine Essentials: Cardiometabolic Self-Assessment
- Translational Endocrinology & Metabolism: Type 2 Diabetes Update
The more you participate, the better your chances. Take part in any of these ways:
Sign up to receive our monthly e-mail newsletter.
Comment on an Expert Blog post.
Vote on and/or add to the discussion of our Case Studies.
Diabetic retinopathy remains a leading cause of visual loss worldwide. Patients with diabetes mellitus commonly have multiple comorbidities treated with a wide variety of medications. Systemic medications that target glycemic control and coexisting conditions may have beneficial or deleterious effects on the onset or progression of diabetic retinopathy. In addition, data is accumulating to suggest that the use of systemic therapy primarily to address ocular complications of diabetic retinopathy may be a promising therapeutic approach. This article reviews our current understanding of the ocular-specific effects of systemic medications commonly used by patients with diabetes mellitus, including those directed at control of hyperglycemia, dyslipidemia, hypertension, cardiac disease, anemia, inflammation and cancer. Current clinical evidence is strongest for the use of angiotensin-converting enzyme inhibitors and angiotensin-2 receptor blockers in preventing the onset or slowing the progression of early diabetic retinopathy. To a more limited extent, evidence of a benefit of fibrates for diabetic macular edema exists. Numerous other agents hold considerable promise or potential risk. Thus, these compounds must undergo further rigorous study to determine the actual clinical efficacy and adverse effects before definitive therapeutic care recommendations can be offered